Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Cornerstone Wealth Group LLC Increases Stake in Boston Scientific ...

AI-generated analysis

πŸ“ˆ Cornerstone Wealth Group LLC increased its stake in Boston Scientific by 1,323.9% in Q1, adding 59,722 shares to a total holding of 64,233 shares.

πŸ’° Border to Coast Pensions Partnership purchased a new stake worth approximately $24.34 million in the first quarter.

πŸ“‰ UBS Group lowered its price target from $120.00 to $105.00 while maintaining a 'buy' rating on the stock.

πŸ“ˆ Needham & Company reaffirmed a 'buy' rating with a price objective of $77.00 for Boston Scientific shares.

πŸ’΅ The company reported Q4 earnings of $0.80 EPS, beating analyst estimates of $0.79 on revenue of $5.20 billion.

πŸ“Š Revenue grew 11.6% year-over-year to $5.20 billion, exceeding the consensus estimate of $5.19 billion.

πŸš€ The Board of Directors approved a new share buyback program authorizing the repurchase of up to $5.00 billion in shares.

πŸ‘” Director David C. Habiger purchased 2,250 shares at an average price of $55.92, increasing his position by 19.35%.

πŸ“‰ The stock currently trades at $44.16, which is below its 50-day moving average of $52.87 and 200-day moving average of $71.13.

🎯 Analyst consensus target price stands at $83.36 with a 'Moderate Buy' rating based on data from MarketBeat.com.

Bullish Signals
  • Cornerstone Wealth Group LLC significantly increased its position by 1,323.9% in Q1, adding 59,722 shares to its holdings.
  • Border to Coast Pensions Partnership initiated a new stake worth approximately $24.34 million in the first quarter.
  • Pictet Asset Management Holding SA boosted its position by 19.1%, acquiring an additional 820,284 shares.
  • The company beat quarterly earnings estimates with $0.80 EPS compared to the consensus of $0.79.
  • Revenue reached $5.20 billion, representing an 11.6% increase year-over-year against analyst expectations.
  • The Board of Directors approved a substantial share buyback program authorizing up to $5.00 billion in repurchases.
  • Director David C. Habiger purchased 2,250 shares at $55.92 per share, increasing his personal stake by nearly 20%.
  • Needham & Company reaffirmed a 'buy' rating with a specific price objective of $77.00.
Risk Factors
  • UBS Group decreased its price target from $120.00 to $105.00, indicating a lower valuation expectation.
  • Leerink Partners lowered its price target from $87.00 to $74.00 despite maintaining an 'outperform' rating.
  • Wolfe Research downgraded the stock from an 'outperform' rating to a 'peer perform' rating.
  • The current stock price of $44.16 is trading significantly below its 50-day moving average of $52.87 and 200-day moving average of $71.13.
Full Analysis
Cornerstone Wealth Group LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1,323.9% in the first quarter, acquiring an additional 59,722 shares to hold a total of 64,233 shares valued at $3.82 million. Several other institutional investors also adjusted their positions, with Border to Coast Pensions Partnership adding a new stake worth approximately $24.34 million and Pictet Asset Management boosting its holdings by 19.1% to own over 5.12 million shares. Analyst sentiment remains mixed regarding the medical device company's valuation. UBS Group lowered its price target from $120.00 to $105.00 while maintaining a 'buy' rating, and Leerink Partners reduced its target from $87.00 to $74.00. Conversely, Needham & Company reaffirmed a 'buy' rating with a $77.00 objective, and Oppenheimer set a target of $90.00. The consensus rating is currently a 'Moderate Buy' with an average price target of $83.36. Financially, Boston Scientific reported strong performance in the last quarter, beating earnings estimates with $0.80 EPS on revenue of $5.20 billion, which represented an 11.6% year-over-year increase. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41. Additionally, the Board of Directors approved a new share buyback program authorizing the repurchase of up to $5.00 billion in shares. Insider activity shows continued confidence from company leadership, with Director David C. Habiger purchasing 2,250 shares and Director Cheryl Pegus acquiring 1,770 shares on May 20th. Combined with the recent buyback authorization, these actions suggest management views the stock as undervalued despite the current trading price of $44.16 being below its 50-day and 200-day moving averages.